{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:39:07Z","timestamp":1792712347184,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.xcrm.2026.103118","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:42:53Z","timestamp":1792593773000},"page":"103118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CNS targeted AAV gene therapies: Recent advances and clinical insights"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1557-5566","authenticated-orcid":false,"given":"Brandon L.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0085-8385","authenticated-orcid":false,"given":"Robert W.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3715-6290","authenticated-orcid":false,"given":"Beverly L.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103118_bib1","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.103118_bib2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuron.2009.03.024","article-title":"Neurodegenerative diseases target large-scale human brain networks","volume":"62","author":"Seeley","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.xcrm.2026.103118_bib4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-term efficacy and safety of eladocagene exuparvovec in patients with AADC deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/43977","article-title":"Virus treatment questioned after gene therapy death","volume":"401","author":"Lehrman","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103118_bib6","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1128\/JVI.74.20.9451-9463.2000","article-title":"Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo","volume":"74","author":"Nakai","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib7","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1038\/s41591-021-01522-3","article-title":"Toxicity after AAV delivery of RNAi expression constructs into nonhuman primate brain","volume":"27","author":"Keiser","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib9","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV vectors in primates","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.ymthe.2024.05.040","article-title":"In vivo selection in non-human primates identifies AAV capsids for on-target CSF delivery to spinal cord","volume":"32","author":"Hanlon","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mt.2015.134","article-title":"Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer","volume":"24","author":"Li","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1208\/s12248-025-01194-8","article-title":"Quantifying the Full-to-Empty Adeno-Associated Virus (AAV) Capsid Ratios and Their Impact on Transduction Efficiency in vitro","volume":"28","author":"Hoyle","year":"2025","journal-title":"AAPS J."},{"key":"10.1016\/j.xcrm.2026.103118_bib15","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated Defective Virus Particles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103118_bib18","doi-asserted-by":"crossref","first-page":"10405","DOI":"10.1073\/pnas.162250899","article-title":"The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy","volume":"99","author":"Xie","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103118_bib19","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1128\/JVI.78.7.3361-3371.2004","article-title":"Structure of Adeno-Associated Virus Serotype 5","volume":"78","author":"Walters","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib20","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41467-021-21935-5","article-title":"Adeno-associated virus capsid assembly is divergent and stochastic","volume":"12","author":"W\u00f6rner","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103118_bib21","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1128\/jvi.62.8.2745-2754.1988","article-title":"Synthesis of adeno-associated virus structural proteins requires both alternative mRNA splicing and alternative initiations from a single transcript","volume":"62","author":"Becerra","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1099\/0022-1317-83-5-973","article-title":"The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity","volume":"83","author":"Girod","year":"2002","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","article-title":"Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics","volume":"55","author":"Hoggan","year":"1966","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103118_bib24","doi-asserted-by":"crossref","first-page":"6381","DOI":"10.1128\/JVI.78.12.6381-6388.2004","article-title":"Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues","volume":"78","author":"Gao","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1128\/JVI.73.2.939-947.1999","article-title":"Human Adeno-Associated Virus Type 5 Is Only Distantly Related to Other Known Primate Helper-Dependent Parvoviruses","volume":"73","author":"Bantel-Schaal","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib26","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225206","article-title":"Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2026.103118_bib28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ymthe.2019.11.005","article-title":"GPR108 Is a Highly Conserved AAV Entry Factor","volume":"28","author":"Dudek","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib29","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature16465","article-title":"An essential receptor for adeno-associated virus infection","volume":"530","author":"Pillay","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103118_bib30","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1016\/j.cell.2025.06.026","article-title":"An alternate receptor for adeno-associated viruses","volume":"188","author":"Dhungel","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103118_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.molmed.2020.09.010","article-title":"Journey to the Center of the Cell: Tracing the Path of AAV Transduction","volume":"27","author":"Dhungel","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02213-17","article-title":"An Alternate Route for Adeno-associated Virus (AAV) Entry Independent of AAV Receptor","volume":"92","author":"Dudek","year":"2018","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.omtm.2020.03.012","article-title":"Pooled Screens Identify GPR108 and TM9SF2 as Host Cell Factors Critical for AAV Transduction","volume":"17","author":"Meisen","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib34","article-title":"Identification of CD164 as an essential entry receptor for divergent adeno-associated viruses","volume":"123","author":"Zhang","year":"2026","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.103118_bib35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1242\/jcs.111.7.877","article-title":"Intracellular trafficking of metallocarboxypeptidase D in AtT-20 cells: Localization to the Trans-Golgi network and recycling from the cell surface","volume":"111","author":"Varlamov","year":"1998","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.xcrm.2026.103118_bib36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.tim.2021.09.005","article-title":"Adeno-associated virus (AAV) cell entry: structural insights","volume":"30","author":"Meyer","year":"2022","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.xcrm.2026.103118_bib37","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00337-26","article-title":"AAV2 bypasses direct endosomal escape by using AAVR to access the trans-Golgi network en route to the nucleus","volume":"100","author":"Cabanes-Creus","year":"2026","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.47","article-title":"Super-resolution imaging of nuclear import of adeno-associated virus in live cells","volume":"2","author":"Kelich","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib39","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1128\/JVI.02660-13","article-title":"Recombinant Adeno-Associated Virus Utilizes Host Cell Nuclear Import Machinery To Enter the Nucleus","volume":"88","author":"Nicolson","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib40","doi-asserted-by":"crossref","first-page":"e0134524","DOI":"10.1128\/jvi.01345-24","article-title":"Structural basis for nuclear import of adeno-associated virus serotype 6 capsid protein","volume":"99","author":"Hoad","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101630","article-title":"Elucidation of the binding interaction interface between AAV serotype 11 capsid protein and host nuclear import proteins","volume":"33","author":"Hoad","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib42","doi-asserted-by":"crossref","first-page":"11776","DOI":"10.1128\/JVI.79.18.11776-11787.2005","article-title":"Green fluorescent protein-tagged adeno-associated virus particles allow the study of cytosolic and nuclear trafficking","volume":"79","author":"Lux","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib43","doi-asserted-by":"crossref","first-page":"7951","DOI":"10.1128\/jvi.71.10.7951-7959.1997","article-title":"Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome","volume":"71","author":"Surosky","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib44","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1128\/JVI.77.6.3495-3504.2003","article-title":"Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle","volume":"77","author":"Schnepp","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib45","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib46","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1128\/JVI.79.1.569-580.2005","article-title":"Viral transport of DNA damage that mimics a stalled replication fork","volume":"79","author":"Jurvansuu","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.113902","article-title":"Capsid-mediated control of adeno-associated viral transcription determines host range","volume":"43","author":"Loeb","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.103118_bib48","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1038\/s41467-023-38106-3","article-title":"The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner","volume":"14","author":"Gonzalez-Sandoval","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103118_bib49","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101434","article-title":"A comprehensive study of AAV tropism across C57BL\/6 mice, BALB\/c mice, and crab-eating macaques","volume":"33","author":"Fang","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib51","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","article-title":"Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue","volume":"27","author":"Thomsen","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors","volume":"12","author":"B\u00fcning","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103118_bib54","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.ymthe.2025.03.057","article-title":"Current trends in gene therapy to treat inherited disorders of the brain","volume":"33","author":"Matuszek","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib55","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib56","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2026.103118_bib57","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.ymthe.2025.04.046","article-title":"Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-brain barrier","volume":"33","author":"Moyer","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib58","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1126\/science.adm8386","article-title":"An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery","volume":"384","author":"Huang","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103118_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr2531","article-title":"An AAV variant selected through NHP screens robustly transduces the brain and drives secreted protein expression in NHPs and mice","volume":"17","author":"Tecedor","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nbt.3440","article-title":"Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain","volume":"34","author":"Deverman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103118_bib61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","article-title":"AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset","volume":"25","author":"Goertsen","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.xcrm.2026.103118_bib62","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/s41467-025-60000-3","article-title":"Optimized AAV capsids for basal ganglia diseases show robust potency and distribution","volume":"16","author":"Leib","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103118_bib63","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed evolution of adeno-associated virus yields enhanced gene delivery vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103118_bib64","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1128\/JVI.00254-08","article-title":"In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib65","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/mt.2009.184","article-title":"Molecular Evolution of Adeno-associated Virus for Enhanced Glial Gene Delivery","volume":"17","author":"Koerber","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib66","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103118_bib67","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.3390\/genes14081660","article-title":"SMRT Sequencing Enables High-Throughput Identification of Novel AAVs from Capsid Shuffling and Directed Evolution","volume":"14","author":"Casy","year":"2023","journal-title":"Genes"},{"key":"10.1016\/j.xcrm.2026.103118_bib68","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1525-0016(03)00123-0","article-title":"In vitro selection of viral vectors with modified tropism: the adeno-associated virus display","volume":"8","author":"Perabo","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib69","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/nbt856","article-title":"Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors","volume":"21","author":"M\u00fcller","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103118_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101629","article-title":"The amazing AAV capsids: Into the structure-verse","volume":"33","author":"Hsi-Bell","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib71","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41565-023-01419-x","article-title":"Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain","volume":"18","author":"Chuapoco","year":"2023","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.xcrm.2026.103118_bib72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/312162a0","article-title":"Transferrin receptor on endothelium of brain capillaries","volume":"312","author":"Jefferies","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103118_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116419","article-title":"AAVs targeting human carbonic anhydrase IV enhance gene delivery to the brain","volume":"44","author":"Lin","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.103118_bib74","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.omtm.2019.07.004","article-title":"GluA4-Targeted AAV Vectors Deliver Genes Selectively to Interneurons while Relying on the AAV Receptor for Entry","volume":"14","author":"Hartmann","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/0271678X16671146","article-title":"The capillary bed offers the largest hemodynamic resistance to the cortical blood supply","volume":"37","author":"Gould","year":"2017","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.xcrm.2026.103118_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54928-y","article-title":"Adeno-associated virus capsid protein expression in Escherichia coli and chemically defined capsid assembly","volume":"9","author":"Le","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2026.103118_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040586","article-title":"Characterization of Recombinant Adeno-Associated Viruses (rAAVs) for Gene Therapy Using Orthogonal Techniques","volume":"13","author":"Cole","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2026.103118_bib78","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.omtm.2023.06.004","article-title":"Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate","volume":"30","author":"Kumar","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105981","article-title":"Local diffusion in the extracellular space of the brain","volume":"177","author":"T\u00f8nnesen","year":"2023","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.xcrm.2026.103118_bib80","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103118_bib81","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.xcrm.2026.103118_bib82","unstructured":"Biotherapeutics C.(2025) A Letter to the STXBP1 Community. https:\/\/capsida.com\/a-letter-to-the-stxbp1-community\/2025."},{"key":"10.1016\/j.xcrm.2026.103118_bib83","unstructured":"Biotherapeutics C.(2026) An Important Update Regarding Our CAP-002 Program: A Letter to the STXBP1 Community. https:\/\/capsida.com\/an-important-update-regarding-our-cap-002-program-a-letter-to-the-stxbp1-community\/2026."},{"key":"10.1016\/j.xcrm.2026.103118_bib84","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41434-022-00346-1","article-title":"Assessment of AAV9 distribution and transduction in rats after administration through Intrastriatal, Intracisterna magna and Lumbar Intrathecal routes","volume":"30","author":"Chandran","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib85","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa2307952","article-title":"Intrathecal Gene Therapy for Giant Axonal Neuropathy","volume":"390","author":"Bharucha-Goebel","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib86","article-title":"Jaguar Gene Therapy Announces Successful Completion of Dosing of First Patient Cohort in Clinical Trial Evaluating JAG201 for the Treatment of a Leading Monogenic Cause of Autism Spectrum Disorder Known as Phelan-McDermid Syndrome","author":"Neer","year":"2026","journal-title":"Buisnesswire"},{"key":"10.1016\/j.xcrm.2026.103118_bib87","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/hum.2006.178","article-title":"Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain","volume":"18","author":"Taymans","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib88","article-title":"Computational modeling and preclinical validation support targeting somatic instability for Huntington\u2019s disease treatment","author":"Simpson","year":"2026","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2026.103118_bib89","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.omtm.2020.10.011","article-title":"CNS Transduction Benefits of AAV-PHP.eB over AAV9 Are Dependent on Administration Route and Mouse Strain","volume":"19","author":"Mathiesen","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib90","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41592-020-0799-7","article-title":"Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types","volume":"17","author":"Ravindra Kumar","year":"2020","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2026.103118_bib91","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1021\/acssynbio.5c00910","article-title":"Receptor-guided AAV tropism engineering via MATCH","volume":"15","author":"Graham","year":"2026","journal-title":"ACS Synth Biol"},{"key":"10.1016\/j.xcrm.2026.103118_bib92","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omtm.2018.12.001","article-title":"Kinetics and MR-Based Monitoring of AAV9 Vector Delivery into Cerebrospinal Fluid of Nonhuman Primates","volume":"13","author":"Ohno","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib93","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41434-020-0178-0","article-title":"Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery","volume":"28","author":"Pietersz","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2014.51","article-title":"Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna","volume":"1","author":"Hinderer","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib95","first-page":"54","article-title":"Cerebrospinal fluid stasis and its clinical significance","volume":"15","author":"Whedon","year":"2009","journal-title":"Alternative therapies in health and medicine"},{"key":"10.1016\/j.xcrm.2026.103118_bib96","doi-asserted-by":"crossref","first-page":"526","DOI":"10.30802\/AALAS-CM-99-990010","article-title":"Flow Rate and Apparent Volume of Cerebrospinal Fluid in Rhesus Macaques (Macaca mulatta) Based on the Pharmacokinetics of Intrathecally Administered Inulin","volume":"70","author":"Lester McCully","year":"2020","journal-title":"Comp. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib97","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1096\/fj.04-1711fje","article-title":"Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1","volume":"19","author":"Oshio","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.xcrm.2026.103118_bib98","first-page":"1982","article-title":"A primate model for study of methotrexate pharmacokinetics in the central nervous system","volume":"37","author":"Poplack","year":"1977","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103118_bib99","unstructured":"Davson H, Welch K, Segal MB. Physiology and Pathophysiology of the Cerebrospinal Fluid. 1987."},{"key":"10.1016\/j.xcrm.2026.103118_bib100","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1517\/17425247.2016.1171315","article-title":"CSF, blood-brain barrier, and brain drug delivery","volume":"13","author":"Pardridge","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.xcrm.2026.103118_bib101","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88034","article-title":"Glymphatic fluid transport controls paravascular clearance of AAV vectors from the brain","volume":"1","author":"Murlidharan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2026.103118_bib102","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.omtm.2020.04.001","article-title":"Intra-CSF AAV9 and AAVrh10 Administration in Nonhuman Primates: Promising Routes and Vectors for Which Neurological Diseases?","volume":"17","author":"Bey","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib103","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s41591-024-02973-0","article-title":"Progranulin AAV gene therapy for frontotemporal dementia: translational studies and phase 1\/2 trial interim results","volume":"30","author":"Sevigny","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib104","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41591-025-04103-w","article-title":"Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial","volume":"32","author":"Proud","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib105","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2601608","article-title":"Neuroepithelial Tumor with AAV Integration after Intracisternal Magna Vector Delivery","volume":"394","author":"Ahrens-Nicklas","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib106","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2026.103118_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113348","article-title":"An ultra-compact promoter drives widespread neuronal expression in mouse and monkey brains","volume":"42","author":"Wang","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.103118_bib108","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.cell.2025.05.002","article-title":"A suite of enhancer AAVs and transgenic mouse lines for genetic access to cortical cell types","volume":"188","author":"Ben-Simon","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103118_bib109","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-024-07556-0","article-title":"A deep catalogue of protein-coding variation in 983,578 individuals","volume":"631","author":"Sun","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103118_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.559998","article-title":"Gene Size Matters: An Analysis of Gene Length in the Human Genome","volume":"12","author":"Lopes","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.xcrm.2026.103118_bib111","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.molcel.2018.12.003","article-title":"A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing","volume":"73","author":"Edraki","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2026.103118_bib112","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","article-title":"Gene Editing for CEP290-Associated Retinal Degeneration","volume":"390","author":"Pierce","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib113","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","article-title":"Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses","volume":"4","author":"Levy","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.xcrm.2026.103118_bib114","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/hum.2008.009","article-title":"Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy","volume":"19","author":"Li","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1167\/tvst.14.11.38","article-title":"The Co-Transduction Conundrum: Improving Dual rAAV Delivery Through Co-Administration of Capsid Serotypes With Complementary Tropism","volume":"14","author":"Fehrman","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.xcrm.2026.103118_bib116","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/hum.2011.200","article-title":"Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates","volume":"23","author":"Samaranch","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib117","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.omtm.2021.10.004","article-title":"Inclusion of a degron reduces levelsof undesired inteins after AAV-mediated proteintrans-splicing in the retina","volume":"23","author":"Tornabene","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.xcrm.2026.103118_bib118","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.103118_bib119","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.103118_bib120","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.103118_bib121","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2025.03.037","article-title":"The curious case of AAV immunology","volume":"33","author":"Keeler","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib122","series-title":"Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Rential Disease: Phase 3 Results at 8 Years and 9 Years","author":"Russel","year":"2024"},{"key":"10.1016\/j.xcrm.2026.103118_bib123","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/15569527.2025.2573463","article-title":"Clinical and pharmacovigilance safety evaluation of LUXTURNA\u00ae(voretigene neparvovec-rzyl)","volume":"44","author":"Simoens","year":"2025","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.xcrm.2026.103118_bib124","doi-asserted-by":"crossref","DOI":"10.3390\/biom14010122","article-title":"Real-World Safety and Effectiveness of Voretigene Neparvovec: Results up to 2 Years from the Prospective, Registry-Based PERCEIVE Study","volume":"14","author":"Fischer","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.xcrm.2026.103118_bib125","article-title":"Understanding and prevention of \u201ctherapy-\u201d induced dyskinesias","volume":"2012","author":"Aviles-Olmos","year":"2012","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.xcrm.2026.103118_bib126","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114712","article-title":"Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease","volume":"13","author":"Hwu","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib127","unstructured":"Novartis. (2022). Zolgensma Acute Liver Failure Update. Novartis. (https:\/\/www.novartis.com\/news\/zolgensma-acute-liver-failure-update)."},{"key":"10.1016\/j.xcrm.2026.103118_bib128","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI79213","article-title":"Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy","volume":"125","author":"Chandler","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.103118_bib129","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.ymthe.2023.08.013","article-title":"Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"31","author":"Retson","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib130","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/j.ymthe.2025.02.025","article-title":"Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec","volume":"33","author":"Holzwarth","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib131","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","article-title":"Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy","volume":"78","author":"Mendell","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.xcrm.2026.103118_bib132","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103118_bib133","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","article-title":"Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial","volume":"28","author":"Strauss","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib134","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210268","article-title":"Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients With Spinal Muscular Atrophy: The Phase 3b SMART Study","volume":"104","author":"McMillan","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.xcrm.2026.103118_bib135","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1089\/hum.2021.255","article-title":"Single-Dose Intrathecal Dorsal Root Ganglia Toxicity of Onasemnogene Abeparvovec in Cynomolgus Monkeys","volume":"33","author":"Tukov","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2026.103118_bib136","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1474-4422(23)00313-7","article-title":"Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial","volume":"22","author":"Shieh","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.xcrm.2026.103118_bib137","unstructured":"Erler W. (2025). Community Letter: Update Regarding ELEVIDYS. Sarepta Therapeutics. (https:\/\/www.sarepta.com\/community-letter-update-regarding-elevidys)."},{"key":"10.1016\/j.xcrm.2026.103118_bib138","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1038\/s41591-025-03750-3","article-title":"AAV mini-dystrophin gene therapy for Duchenne muscular dystrophy: a phase 1b trial","volume":"31","author":"Butterfield","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib139","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103118_bib140","series-title":"MDA Clinical & Scientific Conference 2026","article-title":"Long-term Follow-up of Onasemnogene Abeparvovec Gene Therapy for Patients with Spinal Muscular Atrophy Type 1 from the START Trial","author":"Waldrop","year":"2026"},{"key":"10.1016\/j.xcrm.2026.103118_bib141","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.celrep.2017.07.004","article-title":"The Lifespan and Turnover of Microglia in the Human Brain","volume":"20","author":"R\u00e9u","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.103118_bib142","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.xcrm.2026.103118_bib143","volume":"28","author":"Novartis","year":"2025"},{"key":"10.1016\/j.xcrm.2026.103118_bib144","article-title":"Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.xcrm.2026.103118_bib145","article-title":"Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from 6 infusion centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health. Eur."},{"key":"10.1016\/j.xcrm.2026.103118_bib146","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3233\/JND-230122","article-title":"Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry","volume":"11","author":"Servais","year":"2024","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.xcrm.2026.103118_bib147","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13023-025-03715-2","article-title":"Postmarketing adverse events associated with onasemnogene abeparvovec: a real-world pharmacovigilance study","volume":"20","author":"Chen","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.xcrm.2026.103118_bib148","article-title":"Long-term safety and effectiveness of voretigene neparvovec: 5-year interim results of the PERCEIVE real-world study","author":"Fischer","year":"2025","journal-title":"EURETINA Congress"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:59:41Z","timestamp":1792709981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":148,"alternative-id":["S2666379126005355"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103118","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS targeted AAV gene therapies: Recent advances and clinical insights","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103118"}}